Brief: Oncolytics announces successful end-of-Phase 2 meeting with FDA for reolysin
Sept 18 (Reuters) - Oncolytics Biotech Inc ONC.TO
* Oncolytics Biotech Inc - announces successful end-of-Phase
2 meeting with FDA for reolysin in metastatic breast cancer
* Oncolytics Biotech Inc - FDA provided guidance that if
study achieves its primary endpoint, then it will be only study
required for BLA approval
Source text for Eikon: ID:nPnyn6QXa
Further company coverage: ONC.TO
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Announces Clinical Supply Agreement To Evaluate Pelareorep In Combination With Loqtorzi In Squamous Cell Anal Carcinoma
Brief: Oncolytics Says Pelareorep Shows Durable Survival Benefit in Anal Cancer
Brief: Oncolytics Biotech Expects Final Cohort 4 Results Of Goblet Study In Q4 2026
Brief: Oncolytics Biotech® Secures Patent Protection To Late 2040S And Provides Intellectual Property Portfolio Update
Brief: Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer